01—Abstract
Summary
Summary of the 8-K filed April 14, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (WST) filed this Current Report on Form 8-K on April 14, 2025 to disclose a departure of a named executive officer.
The filing states that Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, departed the Company effective March 7, 2025, and that she was a named executive officer at the time of her departure. Her severance is governed by the Company's standard severance policy and is conditioned on her execution of a release and compliance with certain covenants. Under a Separation Agreement and Release dated as of April 9, 2025 (filed as Exhibit 10.1), Ms. Reiss-Clark will receive one year of salary continuation at her then-current salary of $489,500,a continuation of welfare benefits at the active employee rate, a 2025 payment of $57,526 representing her pro-rated Annual Incentive Plan target, and outplacement services of up to $15,000.
In exchange, she released claims against the Company to the extent permitted by law, agreed not to pursue litigation, reaffirmed her noncompetition and nonsolicitation obligations, agreed to cooperate with the Company as needed, and accepted a mutual nondisparagement provision. For investors, the filing is a routine executive transition disclosure with no reported financial results or guidance. The amounts disclosed are modest relative to the Company's scale, and the filing states that the summary is qualified in its entirety by the full agreement.
02—Key points
Key Highlights
- Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, departed West Pharmaceutical Services effective March 7, 2025.
- Ms. Reiss-Clark was a named executive officer at the time of her departure.
- Severance includes one year of salary continuation at her then-current salary of $489,500.
- A 2025 payment of $57,526, representing her pro-rated Annual Incentive Plan target, is included in the benefits.
- Additional benefits include continued welfare benefits at the active employee rate and up to $15,000 in outplacement services.
- In exchange, Ms. Reiss-Clark released claims, agreed not to litigate, reaffirmed noncompetition and nonsolicitation covenants, and agreed to cooperate as needed; both parties agreed to a nondisparagement provision.
- The Separation Agreement and Release dated April 9, 2025 is filed as Exhibit 10.1.
03—Questions
Frequently Asked Questions
Who departed from West Pharmaceutical Services and when?
Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, departed the Company effective March 7, 2025. The Company announced her departure on that same date.
What severance is Ms. Reiss-Clark receiving?
She is receiving one year of salary continuation at her then-current salary of $489,500, continued welfare benefits at the then-current active employee rate, a 2025 payment of $57,526 (her pro-rated Annual Incentive Plan target), and outplacement services of up to $15,000.
What conditions apply to the severance benefits?
Under the Company's standard severance policy, the benefits are contingent on her execution of a release in favor of the Company and its affiliates and her compliance with certain other covenants. In exchange, she released claims to the extent permitted by law, agreed not to pursue litigation, reaffirmed her noncompetition and nonsolicitation obligations, agreed to cooperate as needed, and agreed to a nondisparagement provision.
Is there a formal agreement governing the separation?
Yes. The Company and Ms. Reiss-Clark reached agreement on a Separation Agreement and Release, a copy of which is filed as Exhibit 10.1 to this Form 8-K. The filing states that its summary is qualified in its entirety by the agreement's detailed terms.
04—Continue